30 October 2020 - The CADTH Canadian Drug Expert Committee has recommended that halobetasol (ulobetasol) propionate with tazarotene (Duobrii) be reimbursed for improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis only if certain conditions are met.

The drug plan cost for halobetasol (ulobetasol) propionate with tazarotene should not exceed the drug plan cost of treatment with the least costly topical combination reimbursed for the treatment of patients with psoriasis.

Read CADTH final recommendation for halobetasol propionate with tazarotene